PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Fesoterodine fumarate - Overactive bladder (adults)
PAD Profile : Fesoterodine fumarate - Overactive bladder (adults) Important
Keywords :
antimuscarinics, OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, urinary urgency, anticholinergics
Brand Names Include :
Toviaz, Teraleve, Zecatrin
Important Information :
3rd line - for patients requiring more potent treatment
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.
05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Fesoterodine is recommended as a 3rd line option in patients who require, and can tolerate, a more potent treatment.
Solifenacin is the 1st line treatment option.
Tolterodine immediate release tablets or Trospium are 2nd line options in patients for whom solifenacin is not suitable.
See Selection Tool for locally agreed OAB treatment options
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence